
Novo Nordisk Maintains Lead in Bidding War for Metsera Amid Pfizer Competition
Novo Nordisk is aggressively increasing its bid to acquire Metsera, surpassing Pfizer's offer amid legal battles and market turmoil, as both companies vie for dominance in the weight-loss drug market.
